Labetalol Plus Magnesium Sulfate Lowers Intraoperative BP Variability in HDP Cesarean

This retrospective cohort suggests adding intravenous magnesium sulfate to oral labetalol stabilizes intraoperative blood pressure and improves early neonatal outcomes in hypertensive disorders of pregnancy undergoing cesarean delivery.

labetalolmagnesium sulfatehypertensive disorders of pregnancypreeclampsiacesarean deliveryblood pressure variabilitybeta-blockerobstetric pharmacologyretrospective cohortpropensity score matching Women's Health / Reproductive

Background Information

Labetalol and magnesium sulfate stabilize blood pressure in cesarean deliveries.

Managing blood pressure during cesarean delivery in patients with hypertensive disorders of pregnancy is crucial for maternal and neonatal safety. The combination of labetalol and magnesium sulfate significantly reduced intraoperative systolic blood pressure variability and improved neonatal Apgar scores compared to labetalol alone. This study supports using labetalol with magnesium sulfate to achieve more stable intraoperative blood pressure and better neonatal outcomes in hypertensive pregnancies. Labetalol with magnesium sulfate offers superior intraoperative blood pressure control and neonatal outcomes in cesarean deliveries for hypertensive pregnancies.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Gao C, Lv J

Citation: Gao C, Lv J Comparison of Labetalol With Versus Without Magnesium Sulfate on Intraoperative Blood Pressure Variability During Cesarean Delivery in Hypertensive Disorders of Pregnancy: A Retrospective Cohort Study. Annali italiani di chirurgia. 2026;97(8):1471-1479. doi:10.62713/aic.4542

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →